Trastuzumab in combination with capecitabine plus cisplatin for the
treatment of advanced HER2-positive gastric cancer: A systematic review
and meta-analysis
Abstract
Purpose:The primary objective of this study was to
comprehensively evaluate and compare the therapeutic efficacy of
trastuzumab in combination with capecitabine plus cisplatin versus
capecitabine plus cisplatin in the management of patients diagnosed with
advanced human epidermal growth factor receptor 2 (HER2)-positive
gastric cancer. Aiming to facilitate clinical decision-making and
ultimately improving treatment outcomes for this specific patient
population. Methods:A comprehensive computerized search was
conducted across multiple databases, including Cochrane Library, Web of
Science, PubMed, Embase, CNKI, CBM, VIP, and Wanfang to identify
domestic and foreign clinical randomized controlled trials (RCTs),
investigating the efficacy of trastuzumab in combination with
capecitabine plus cisplatin for the treatment of patients with advanced
HER2-positive gastric cancer. The search encompassed articles published
from the inception of the databases until July 1, 2022.
Results:This meta-analysis comprised 12 studies involving a
total of 1199 patients diagnosed with advanced HER2-positive gastric
cancer. The results revealed that the experimental group exhibited
significantly higher rates of total effectiveness and control compared
to the control group. Moreover, the experimental group showed a
significant increase in median survival time compared to the control
group. Additionally, the experimental group exhibited a significantly
higher quality of life score and demonstrated improved prognosis in
terms of carbohydrate antigen 19-9 (CA19-9) levels, with a lower
recurrence rate. The experimental group showed a decrease in the stage
of gastric cancer based on carbohydrate antigen 72-4 (CA72-4) levels and
(CEA) levels compared to the control group.. Furthermore, the
experimental group exhibited a notable enhancement in the therapeutic
efficacy of vascular endothelial growth factor (VEGF) and a superior
prognosis compared to the control group.
Conclusion:Trastuzumab in combination with capecitabine plus
cisplatin can be a preferred first-line treatment option for advanced
HER2-positive gastric cancer, accompanying by a promising therapeutic
efficacy.